Pharming Group NV ADR Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $376.1M+26.5% YoYTTM through 31 Dec 2025
Net Income $2.5MTTM through 31 Dec 2025
Free Cash Flow $54MTTM through 31 Dec 2025
Margins
| Current | |
|---|---|
| Gross Margin | 87.9% |
| EBITDA Margin | 8.6% |
| Operating Margin | 6.9% |
| Net Margin | 0.7% |
Returns
0.9%ROE
0.5%ROA
1.1%ROIC
Balance Sheet Health
Debt / Equity0.33x
Current Ratio2.59x
Net Debt-$52.6Mnet cash position
Cash & Equivalents$145.3M
Quality Metrics
Piotroski F-Score5 / 9
FCF Margin14.3%
Rule of 4016.1
Earnings-Beat Rate75.0%
Multi-Year Trend
Diluted EPSFY2025: $0.00
Dividend
No dividend
Capital Allocation
Capex Intensity0.2%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| RUCONEST® | $317.9M | +26.1% | View detailsContinued growth expected in the acute HAE market. |
| Joenja® (leniolisib) | $58.2M | +29.3% | View detailsSignificant and accelerating growth expected in U.S. and ex-U.S. markets. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.